Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience

Article Clinical Neurology

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

Chiara Starvaggi Cucuzza et al.

Summary: This study aimed to determine the clinical and neuroradiologic disease activity, as well as B-cell repopulation dynamics, after implementing extended rituximab dosing in RRMS. The results showed that extended dosing intervals did not increase the risk of relapse in RRMS, and the dynamics of total B-cell and memory B-cell repopulation varied considerably.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

添加到收藏夹

Article Clinical Neurology

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

Aurora Zanghi et al.

Summary: In the COVID-19 pandemic era, safety concerns have been raised regarding the risk of severe infection following administration of ocrelizumab (OCR), a B-cell-depleting therapy. This study found that extended interval dosing (EID) of OCR treatment was associated with an increased risk of MRI activity, but did not have a significant impact on confirmed disability progression (CDP). Therefore, EID should be carefully considered for OCR-treated patients.

NEUROTHERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

Barbara Barun et al.

Summary: The study evaluated the effects of delaying ocrelizumab infusions during the COVID-19 pandemics in people with multiple sclerosis. It was found that delaying the dosing of ocrelizumab did not have clinical consequences, but was an independent predictor of B cell repopulation.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation

Nitin Kumar Sahi et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

F. Tazza et al.

Summary: During the SARS-CoV-2 pandemic, personalized delayed protocol for ocrelizumab infusions in RRMS patients was effective in guiding re-infusions based on immunophenotyping, showing no compromise in short-term efficacy due to treatment delays.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Clinical Neurology

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

Maria Pia Sormani et al.

Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Leoni Rolfes et al.

Summary: The study found that extending interval dosing of ocrelizumab for RRMS patients during the COVID-19 pandemic did not result in decreased effectiveness compared to standard interval dosing. Both treatment regimens were effective in maintaining clinical stability and preventing disease progression.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

添加到收藏夹

Article Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Alan J. Thompson et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Monitoring B-cell repopulation after depletion therapy in neurologic patients

Erik Ellwardt et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)

添加到收藏夹

Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience

相关参考文献

导出引文

分享论文